A Paradigm Shift in Cardiovascular Stenting


Our proprietary stent design is a paradigm shift in cardiovascular stenting. The design’s sixth generation, the EluNIR drug eluting stent, relieves physicians from compromising between vessel conformability, scaffolding integrity, uniform drug distribution and radial support by offering an integrated design maximizing all benefits simultaneously.

Low Metal Footprint Variable Width Design

40µm Ultra Narrow Struts

Provides flexibility and conformability.

Optimal Scaffolding Area

Provides uniform support and drug elution while preventing tissue prolapse.

72µm struts

Provides excellent radial strength.

Design Benefits

Optimized Cell Size

Natural vessel curvature and myocardial contractions test the limits of stent design and scaffolding integrity. WiZeCell’s optimized cell size ensures uniform scaffolding and prevents tissue prolapse and strut overlap.

Highly-Uniform Scaffolding

The highly-uniform scaffolding conforms to vessel anatomy and moves dynamically with the vessel, reducing trauma to vessel-wall tissue and the resulting inflammation that can lead to restenosis.

Ultra-Narrow Struts & Narrow Supportive Struts

Medinol’s WiZeCell architecture, with its unique combination of flexible ultra-narrow struts and narrow supportive struts, minimizes variations in inter-strut gaps, even in sharp vessel bends and during systolic cycles.

Medinol WiZeCell
WiZeCell design enables uniform scaffolding
Competitor A
Competitors stent designs enable large openings contributing to tissue prolapse.
Competitor B
Competitor C

Accessibility Toolbar